2019³â ´ëÇÑÆó¾ÏÇÐȸ Ãß°èÇмú´ëȸ : 2019-11-22±³À°ÀÏÀÚ : 2019-11-22
±³À°Àå¼Ò : Àá½Ç ·Ôµ¥È£ÅÚ Å©¸®½ºÅ»·ë
±³À°ÁÖÁ¦ :
2019³â ´ëÇÑÆó¾ÏÇÐȸ Ãß°èÇмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
´ã´çÀÚ : ±èÀÎÁ¤
¿¬¶ôó : 02-741-8540
À̸ÞÀÏ :
kalc@naver.com ±³À°Á¾·ù : ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, ÇÙÀÇÇаú
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 10 ½Ã°£ 25ºÐ
¼¼ºÎ¼ö°·á : 70,000¿ø
ºñ°í »çÀüµî·Ï(Àü¹®ÀÇ): 5¸¸¿ø ÇöÀåµî·Ï(Àü¹®ÀÇ): 7¸¸¿ø ÇöÀåµî·Ï(Àü°øÀÇ/Çлý/ÀüÀÓÀÇ/°£È£»ç/±âŸ): 5¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2 09:25~09:50 Multiplexed omics approach in lung cancer research ±èÅÂÁ¤(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2 09:50~10:15 Towards successful cancer vaccine development ±èÁß±Ô(ÆèÅä¹ÙÀÌ¿À¸Þµå)
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2 10:15~10:40 Cell and gene therapy for lung cancer Sam Janes(University College London Hospitals)
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 3 09:00~09:25 Oncologic outcomes of segmentectomy in early lung cancer ±èÈ«°ü(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 3 09:25~09:50 Application of navigation bronchoscopy in lung cancer surgery ¹ÚÀαÔ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 3 09:50~10:15 Single Port Lung Cancer Surgery ±èÇö±¸(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 3 10:15~10:40 Image-guided surgery in lung cancer ÀÌ⿵(¿¬¼¼ÀÇ´ë)
ÈÞ½Ä 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 10:40~11:10 ÈÞ½Ä ()
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 11:10~11:50 Whole genomic landscape of pre-invasive lung cancer lesions Sam Janes(University College London Hospitals)
Åä·Ð 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 11:50~12:00 Q & A Sam Janes(University College London Hospitals)
½Ä»ç 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 12:00~12:40 Luncheon Symposium II. °ÁøÇü(°¡Å縯ÀÇ´ë)
ÈÞ½Ä 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 12:40~13:00 ÃÑȸ ()
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 13:00~13:20 Æó¾Ïº´±âÁ¶»ç»ç¾÷(KALC R)ÀÇ °æ°ú ¹× ¹ßÀü ¹æÇâ ÃÖâ¹Î(¿ï»êÀÇ´ë)
ÈÞ½Ä 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 13:20~13:40 ()
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2 13:40~14:05 Overcoming Resistance to first-line osimertinib in EGFR-mutant lung cancer ÀÌÀ±±Ô(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2 14:05~14:30 Emerging therapies for Resistance of ALK-Targeted Therapies À̽·æ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2 14:30~14:55 Resistance Mechanisms to BRAF/MEK inhibition in BRAF-mutant lung cancer À±½Å±³(¿ï»êÀÇ´ë)
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2 14:55~15:20 Emerging Rare Targets beyond EGFR/ALK/ROS1/BRAF in Lung Cancer ±èÀ¯Á¤(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 3 13:40~14:05 Lung cancer screening in Korea: Potential future directions Àå½ÂÈÆ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 3 14:05~14:30 Lung cancer screening in Korea: Lessons the K-LUCAS ±è¿(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 3 14:30~14:55 Lung cancer screening with low-dose CT: What we have learned ±¸Áø¸ð(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 3 14:55~15:20 Lung-RADS: All you need to know ±èÇý¿µ(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 2,3 15:20~15:40 History and current status of the new tobacco products ±èÀ¯ÀÏ(Àü³²ÀÇ´ë)
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 2,3 15:40~16:00 Safety assessment of the new tabacco products ¹ÚÇýÁ¤(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 2,3 16:00~16:20 Regulatory strategies in perspective of population science for the new tobacco products ±èÈñÁø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1 15:20~16:20 Oral Presentation III. À̰DZ¹(±¹¸³¾Ï¼¾ÅÍ)
ÈÞ½Ä 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 16:20~16:50 ÈÞ½Ä ()
Åä·Ð 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 16:50~17:20 Topic I. Local Treatment for Oligometastases Á¶¼®±â(¼¿ïÀÇ´ë)
Åä·Ð 11-22 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 17:20~17:50 Topic II. Harmonizing systemic therapy with local treatment for oligometastases È«¹ÎÈñ(¿¬¼¼ÀÇ´ë)